Open AccessCGRP antagonists: Perspectives on migraine prophylaxis
Author(s) -
Nathalia Lima Schramm dos Santos,
William Wallace dos Santos Silva,
Geovanna da Silva Campos Conceição,
Gabriel Serra Almeida,
Jacqueline Oliveira Freitas,
Breno Silva Reis,
Lucas Santos Silva
Publication year - 2021
Language(s) - English
Resource type - Conference proceedings
DOI - 10.5327/1516-3180.193
Subject(s) - migraine , medicine , calcitonin gene related peptide , adverse effect , placebo , intensive care medicine , clinical trial , disease , triptans , randomized controlled trial , alternative medicine , pathology , receptor , neuropeptide
Migraine is a neurovascular disease characterized by headache attacks. Currently there are several preventive therapeutic strategies available, however some patients are not very responsive. Thus, more effective treatments have been researched, like the antagonists of the Calcitonin Gene Related Peptide, the Gepants. Objectives: To evaluate the effectiveness of Gepants in the treatment of migraine. Methods: This is an integrative literature review in the PubMed database, using the descriptors “gepants”, “migraine” and “efficacy”. Only randomized clinical trials conducted from January 2018 to September 2020 were included. Results: Twenty studies were listed, of which 17 use Gepants as a preventive treatment, 2 in acute use and 1 pharmacodynamic study. The Gepants have proved to be a viable option for patients irresponsible to the usual prophylactic regimens. Its significance in reducing migraine and associated symptoms is approximately 50% compared to the placebo group. Evidence of efficacy in the acute crisis is still insufficient. The adverse effects observed had not clinical impact, but more investigations are necessary since most studies exclude people with heart, liver and chronic kidney disease. Another limitation was the use of placebo as a control, not the current prophylactic regimens. Conclusion: This review points to Gepants as a viable option in patients with migraine resistant to the usual regimens. However, there is a need for further studies on adverse effects, comparison with current therapies, drug and pathological interactions.